At this juncture, the adverse reactions were predominantly classified as “aspartate aminotransferase increased” and “alanine aminotransferase increased,” “thrombocytopenia,” “platelet count decreased,” and “vomiting.” These observations suggested an activation of the body’s immune response to the treatment. The gene discussed is GPT; the disease is Thrombocytopenia.